Dermatitis News

The skin of children with early-onset atopic dermatitis exhibits significantly different phenotypes when compared with the skin of adults with a long-standing history with the disease, according to research published in The Journal of Allergy and Clinical Immunology.

BOSTON — Advances in the understanding of epigenetic modifications — changes in gene activity without changes in DNA sequencing — could lead to the development of new biomarkers and potential therapies for immune-modulated inflammatory diseases, according to a presentation given at the Interdisciplinary Autoimmune Summit.

BOSTON — Rheumatologists, gastroenterologists, dermatologists, immunologists and other health care providers who care for patients with immune-mediated inflammatory diseases will gather at the Interdisciplinary Autoimmune Summit in Boston this weekend for a collaborative discussion of treatment strategies.

Many rheumatic diseases – including systemic lupus erythematous, scleroderma and the various forms of psoriasis – present with a multitude of dermatologic symptoms that clinicians can easily confuse with other conditions.

A 300-mg dose of Dupixent weekly or every 2 weeks significantly improved peak itch scores among patient with moderate-to-severe atopic dermatitis, according to research presented at the American Academy of Dermatology annual meeting.

Eosinophilic esophagitis is most likely to be experienced by children after atopic dermatitis, food allergy or asthma, with statistical concurrence with allergic rhinitis, according to a study presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology in Orlando.

An over-the-counter moisturizing hand cream safely and effectively improved eczema symptoms and lesions, according to research presented at the American Academy of Dermatology Annual Meeting.

In the United States, ED visits for eczema are common, seem to be rising and contribute to a substantial cost-burden, according to findings presented at the American Academy of Dermatology Annual Meeting.

The FDA granted breakthrough therapy designation to upadacitinib for the treatment of moderate-to-severe atopic dermatitis in adults who are eligible for systemic therapy, according to the drug’s manufacturer.

Non-Hispanic black children in the United States were less likely to report ambulatory health care visits to treat eczema than non-Hispanic white and Hispanic children.